[HTML][HTML] Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer's clinical trial participants
CD Morales, D Cotton-Samuel, PJ Lao… - Alzheimer's Research & …, 2024 - Springer
Background Secondary prevention clinical trials for Alzheimer's disease (AD) target amyloid
accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent …
accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent …
[HTML][HTML] Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer's clinical trial participants
CD Morales, D Cotton-Samuel… - Alzheimer's …, 2024 - alzres.biomedcentral.com
Secondary prevention clinical trials for Alzheimer's disease (AD) target amyloid
accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent …
accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent …
Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer's clinical trial participants.
CD Morales, D Cotton-Samuel, PJ Lao… - Alzheimer's …, 2024 - search.ebscohost.com
Background: Secondary prevention clinical trials for Alzheimer's disease (AD) target amyloid
accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent …
accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent …
Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer's clinical trial participants.
CD Morales, D Cotton-Samuel, PJ Lao… - … Research & Therapy, 2024 - europepmc.org
Background Secondary prevention clinical trials for Alzheimer's disease (AD) target amyloid
accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent …
accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent …
Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer's clinical trial participants
CD Morales, D Cotton-Samuel… - … research & therapy, 2024 - pubmed.ncbi.nlm.nih.gov
Background Secondary prevention clinical trials for Alzheimer's disease (AD) target amyloid
accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent …
accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent …
[HTML][HTML] Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer's clinical trial participants
CD Morales, D Cotton-Samuel, PJ Lao… - … Research & Therapy, 2024 - ncbi.nlm.nih.gov
Background Secondary prevention clinical trials for Alzheimer's disease (AD) target amyloid
accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent …
accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent …
[PDF][PDF] Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer's clinical trial participants
CD Morales, D Cotton‑Samuel, PJ Lao, JF Chang… - 2024 - alzres.biomedcentral.com
Background Secondary prevention clinical trials for Alzheimer's disease (AD) target amyloid
accumulation in asymp‑tomatic, amyloid‑positive individuals, but it is unclear to what extent …
accumulation in asymp‑tomatic, amyloid‑positive individuals, but it is unclear to what extent …
Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer's clinical trial participants.
CD Morales, D Cotton-Samuel, PJ Lao… - … Research & Therapy, 2024 - europepmc.org
Background Secondary prevention clinical trials for Alzheimer's disease (AD) target amyloid
accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent …
accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent …